Physician profile
John D Long
NPI 1386619393
$6,542.48
in general payments reported to CMS, 2019-2025
29 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $548 · 2021: $555 · 2022: $1,044 · 2023: $1,040 · 2024: $812 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.32 |
| Education | $149.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,054.51 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,027.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $794.05 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $583.15 | 2019-2022 | |
| Ardelyx, INC. | $482.11 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.68 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Exact Sciences Corporation | $270.92 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $256.41 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $225.24 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $181.90 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $172.02 | 2019 | |
| Pfizer INC. | $163.67 | 2019-2022 | |
| Olympus America INC. | $161.12 | 2019-2021 | |
| Erbe USA INC | $142.61 | 2022 | |
| Ironwood Pharmaceuticals, INC | $125.56 | 2019-2024 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $112.70 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $80.04 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $46.95 | 2024-2025 | Voquezna |
| Celgene Corporation | $33.59 | 2022-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $33.30 | 2024 | |
| Celltrion USA INC. | $28.01 | 2024 | Zymfentra |
| Shield Therapeutics INC | $26.79 | 2023 | Accrufer |
| Abbott Laboratories | $24.67 | 2021 | |
| Ucb, INC. | $22.90 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.24 | 2023 | |
| Novo Nordisk INC | $20.49 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $18.37 | 2019 | |
| Allergan, INC. | $12.42 | 2020 | |
| Lilly USA, LLC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.